Evidence map›Paper›PMID 27857134›Full record

ArticleNature communications2016

Germline-encoded neutralization of a Staphylococcus aureus virulence factor by the human antibody repertoire.

Yik Andy Yeung, Davide Foletti, Xiaodi Deng, Yasmina Abdiche, Pavel Strop, Jacob Glanville, Steven Pitts, Kevin Lindquist, Purnima D Sundar, Marina Sirota and 8 more

Open access · goldAbstract read
In one paragraph

Article in Nature communications, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed
3.4field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 48 citations in OpenAlex.

  1. Protective near-germline antibodies to malaria elicited by RTS,S/AS01bioRxiv : the preprint server for biology · 2026
    Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 1 institution in 1 country.

Yik Andy YeungRinat R&D, Pfizer Inc., 230 East Grand Avenue, South San Francisco, California 94080, USA.
Davide FolettiRinat R&D, Pfizer Inc., 230 East Grand Avenue, South San Francisco, California 94080, USA.
Xiaodi DengRinat R&D, Pfizer Inc., 230 East Grand Avenue, South San Francisco, California 94080, USA.
Yasmina AbdicheRinat R&D, Pfizer Inc., 230 East Grand Avenue, South San Francisco, California 94080, USA.
Pavel StropRinat R&D, Pfizer Inc., 230 East Grand Avenue, South San Francisco, California 94080, USA.
Jacob GlanvilleRinat R&D, Pfizer Inc., 230 East Grand Avenue, South San Francisco, California 94080, USA.
Steven PittsRinat R&D, Pfizer Inc., 230 East Grand Avenue, South San Francisco, California 94080, USA.
Kevin LindquistRinat R&D, Pfizer Inc., 230 East Grand Avenue, South San Francisco, California 94080, USA.
Purnima D SundarRinat R&D, Pfizer Inc., 230 East Grand Avenue, South San Francisco, California 94080, USA.
Marina SirotaRinat R&D, Pfizer Inc., 230 East Grand Avenue, South San Francisco, California 94080, USA.
Adela Hasa-MorenoRinat R&D, Pfizer Inc., 230 East Grand Avenue, South San Francisco, California 94080, USA.
Amber PhamRinat R&D, Pfizer Inc., 230 East Grand Avenue, South San Francisco, California 94080, USA.
Jody Melton WittRinat R&D, Pfizer Inc., 230 East Grand Avenue, South San Francisco, California 94080, USA.
Irene NiRinat R&D, Pfizer Inc., 230 East Grand Avenue, South San Francisco, California 94080, USA.
Jaume PonsRinat R&D, Pfizer Inc., 230 East Grand Avenue, South San Francisco, California 94080, USA.
David SheltonRinat R&D, Pfizer Inc., 230 East Grand Avenue, South San Francisco, California 94080, USA.
Arvind RajpalRinat R&D, Pfizer Inc., 230 East Grand Avenue, South San Francisco, California 94080, USA.
Javier Chaparro-RiggersRinat R&D, Pfizer Inc., 230 East Grand Avenue, South San Francisco, California 94080, USA.
Pfizer (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Staphylococcus aureus is both an important pathogen and a human commensal. To explore this ambivalent relationship between host and microbe, we analysed the memory humoral response against IsdB, a protein involved in iron acquisition, in four healthy donors. Here we show that in all donors a heavily biased use of two immunoglobulin heavy chain germlines generated high affinity (pM) antibodies that neutralize the two IsdB NEAT domains, IGHV4-39 for NEAT1 and IGHV1-69 for NEAT2. In contrast to the typical antibody/antigen interactions, the binding is primarily driven by the germline-encoded hydrophobic CDRH-2 motifs of IGHV1-69 and IGHV4-39, with a binding mechanism nearly identical for each antibody derived from different donors. Our results suggest that IGHV1-69 and IGHV4-39, while part of the adaptive immune system, may have evolved under selection pressure to encode a binding motif innately capable of recognizing and neutralizing a structurally conserved protein domain involved in pathogen iron acquisition.

Indexed as

Antibodies, BacterialAntibodies, NeutralizingBacterial ProteinsB-LymphocytesHumansImmunologic MemoryModels, MolecularProtein ConformationProtein DomainsRNA, Long NoncodingStaphylococcal InfectionsStaphylococcus aureusVirulence FactorsAntibodies, BacterialAntibodies, NeutralizingBacterial ProteinsMALAT1 long non-coding RNA, humanNEAT1 long non-coding RNA, humanRNA, Long NoncodingVirulence Factors

Identifiers

PMID27857134
PMCPMC5120205
OpenAlexW2549154422

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.